Sector News

Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro

October 23, 2014
Life sciences
Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and its antibody-drug conjugates and bispecifics. And Celgene is expanding their collaboration to include immuno-oncology drugs, the hottest R&D field in biotech.
 
In the development deal South San Francisco-based Sutro gets $95 million upfront, which includes an equity stake, $90 million during the research stage and more than $1 billion in total, including potential milestones. The two companies will work on PD-1 and PD-L1 targets, an immensely promising field that is bringing an effective immune response to fight cancer for the first time. And out of the mix Sutro can retain certain commercial rights to its products–provided Celgene doesn’t go ahead and close the deal with a buyout under prespecified terms, which are being kept quiet for now.
 
Sutro’s team believes it has devised a much better way to build ADCs–those precise cancer cell-killing constructs made up of a targeting antibody, linker and payload–and bispecifics, teeing up potentially best-in-class products that promise to be more efficiently and consistently manufactured. Using biochemical synthesis, they’ve hatched a technology that can bypass the current approach to biologics by genetically engineering drugs that are much simpler to make, more akin to small molecules. Their technology, which can be deployed with multiple warheads, has not only attracted Celgene; Johnson & Johnson ($JNJ), Sanofi ($SNY) and Merck KGaA have all signed on as partners.
 
Sutro was a 2014 Fierce 15 company.
 
There are plenty of precedents now to demonstrate that checkpoint inhibitors from companies like Merck, Bristol-Myers Squibb and Roche can have a significant impact on overall survival, says Trevor Hallam, the CSO at Sutro. “The consensus is that’s a bit of a given now,” he says.
 
Sutro’s technology, he says, has the potential to quickly come up with candidates that can bind to–or avoid–multiple target sites on checkpoint pathways. That way next-gen combination therapies can both steer clear of “common and limiting side effects” while fine-tuning delivery and allowing investigators to safely amp up the dosage.
 
“It’s really an important deal for our company,” says CEO Bill Newell. Sutro now has 70 staffers and will continue to grow over the next 18 months as these new Celgene programs are brought online and it pursues its own in-house products as well as a collaboration with Merck KGaA.
 
Over the past few years Celgene’s partnering group under George Golumbeski has been scouring the global industry to partner or buy the most interesting new technologies in the field, particularly zeroing in on a number of cancer programs, including a CAR-T partnership it has with bluebird bio. CEO Bob Hugin has made partnering and M&A a top priority at the company, determined to diversify the company’s portfolio while gambling billions of dollars on the outcome. And whatever they have learned about Sutro in the past two years has only whetted their appetite.
 
“Substantive progress and unique advantages of Sutro’s platform have led us to expand and extend our relationship, as a key capability supporting our emerging immuno-oncology pipeline,” says Celgene R&D chief Tom Daniel in a statement. “We see this collaboration as a unique opportunity to accelerate the evaluation and development of important products in this and other strategic areas of high potential impact. Sutro has been a strong partner expanding a potentially disruptive technology, and we look forward to building on the existing collaboration.”
 
By John Carroll
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).